A Peptide Based Vaccine for Prevention and Cure of Rheumatoid Arthritis

Reference #:

MMV-95-017

Inventors/Contributors

Chella S. David, Ph.D., Harvinder S. Luthra, M.D.

Description

Generation of synthetic peptides (15-20 amino acids) that will specifically bind to the major histocompatibility complex class II molecules in the human, which are involved in susceptibility to rheumatoid arthritis. [Immune Response of HLA-DQ8 Transgenic Mice to Peptides from the Third Hypervariable Region of HLA-dRB1 Correlates with Predisposition to Rheumatoid Arthritis, Zanelli, et. al, PNAS 93:1814-1819, 1996] Transgenic mice expressing the DQB1*0302/DQA1*0301 (DQ8) genes in the absence of endogenous mouse class II molecules can be used to analyze the antigenicity of peptides covering the HV3 regions of rheumatoid arthritis (RA) associated and nonassociated DRB1 molecules.

Patent Status

	U.S. Patent Number 5,965,787 Issued October 12, 1999